Piramal Pharma Limited has reported its financial results for the quarter and financial year ended March 31, 2026. The company announced both standalone and consolidated financial outcomes alongside key strategic management appointments and a change in its registered office address. The board approved the re-appointment of senior leadership and confirmed its commitment to robust enterprise governance as it continues to expand its global footprint across 100+ countries through its diversified pharmaceutical portfolio.
Financial Performance Highlights
For the quarter ended March 31, 2026, the company recorded consolidated revenue from operations of ₹2,751.77 crore. For the full financial year 2026, consolidated revenue reached ₹8,869.08 crore. The standalone financial results reported a profit after tax of ₹261.63 crore for the final quarter and ₹700.01 crore for the full financial year.
Strategic Leadership Changes
The Board of Directors approved the re-appointment of several key leaders to ensure continuity and strategic growth. Ms. Nandini Piramal has been re-appointed as Whole-Time Director, designated as Executive Director and Chairperson, effective April 1, 2027, for a period of three years. Additionally, Mr. Peter DeYoung was re-appointed as Whole-Time Director designated as Executive Director, effective October 6, 2026, for three years.
Independent director appointments were also strengthened with the re-appointment of Mr. Sridhar Gorthi and Mr. Peter Stevenson for a second term of five years, effective March 30, 2027. In the corporate office, Mr. Maneesh Sharma has been appointed as the new Company Secretary and Compliance Officer, effective April 29, 2026.
Operational Updates
The company announced a change in its registered office address. Effective April 30, 2026, the registered office will transition to: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070. This move aligns with the company’s ongoing infrastructure and operational optimization efforts.
Exceptional Items and Impairment
During the fiscal year, the company recognized an impairment charge of ₹65.57 crore in standalone results and ₹175.82 crore in consolidated results related to intangible assets under development. These adjustments were part of the annual assessment conducted in accordance with accounting standards.
Source: BSE
